Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marcel van der Weiden is active.

Publication


Featured researches published by Marcel van der Weiden.


Cancer | 2006

Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas

Erkan Kurt; Ping-Pin Zheng; Wim C. J. Hop; Marcel van der Weiden; Meike Bol; Martin J. van den Bent; C. J. J. Avezaat; Johan M. Kros

The results of attempts to identify histopathologic parameters that contribute to the clinical outcome of patients with ependymomas have been controversial. This may be due to the relative rareness of ependymomas. Furthermore, in many investigations, myxopapillary ependymomas and subependymomas were included and may have confounded results, because those tumors should be considered clinicopathologic entities distinct from the other ependymomas.


Journal of Proteome Research | 2011

Serum levels of pregnancy zone protein are elevated in presymptomatic alzheimer's disease

Linda IJsselstijn; Lennard J. M. Dekker; Christoph Stingl; Marcel van der Weiden; Albert Hofman; Johan M. Kros; Peter J. Koudstaal; Peter A. E. Sillevis Smitt; M. Arfan Ikram; Monique M.B. Breteler; Theo M. Luider

We have sought for disease-related proteins that could predict the onset of Alzheimers disease (AD) in a study population derived from the Rotterdam Scan Study, a population-based prospective cohort study designed to investigate the etiology and natural history of age-related brain changes in the elderly. The serum proteome of 43 persons who developed AD, after an average of 4.2 years (±2.6 years SD) after blood sampling, and 43 gender- and age-matched controls who remained dementia-free during follow-up was investigated by liquid chromatography mass spectrometry. We identified 61 differentially expressed peptides between presymptomatic AD and controls, 9 of which were derived from pregnancy zone protein (PZP). Quantitative measurements using a multiple reaction monitoring assay showed a significant increase in concentration of PZP in presymptomatic AD (34.3 ± 20.6 mg/L) compared with controls (23.6 ± 13.6 mg/L) (p = 0.006). The difference in PZP was significant in women. Immunohistochemical validation of the findings on brain tissue sections showed strong PZP expression in senile plaques and in microglial and glial cells in AD with only low expression in some scattered glial cells in controls.


Journal of Neuropathology and Experimental Neurology | 2013

FBXO7 immunoreactivity in α-synuclein-containing inclusions in Parkinson disease and multiple system atrophy.

Tianna Zhao; Lies-Anne Severijnen; Marcel van der Weiden; Ping Pin Zheng; Ben A. Oostra; Renate K. Hukema; Rob Willemsen; Johan M. Kros; Vincenzo Bonifati

Mutations in the gene encoding the F-box only protein 7 (FBXO7) cause PARK15, an autosomal recessive form of juvenile parkinsonism. Although the brain pathology in PARK15 patients remains unexplored, in vivo imaging displays severe loss of nigrostriatal dopaminergic terminals. Understanding the pathogenesis of PARK15 might therefore illuminate the mechanisms of the selective dopaminergic neuronal degeneration, which could also be important for understanding idiopathic Parkinson disease (PD). The expression of FBXO7 in the human brain remains poorly characterized, and its expression in idiopathic PD and different neurodegenerative diseases has not been investigated. Here, we studied FBXO7 protein expression in brain samples of normal controls (n = 9) and from patients with PD (n = 13), multiple system atrophy (MSA) (n = 5), Alzheimer disease (AD) (n = 5), and progressive supranuclear palsy (PSP) (n = 5) using immunohistochemistry with 2 anti-FBXO7 antibodies. We detected widespread brain FBXO7 immunoreactivity, with the highest levels in neurons of the cerebral cortex, putamen, and cerebellum. There were no major differences between normal and PD brains overall, but FBXO7 immunoreactivity was detected in large proportions of α-synuclein-positive inclusions (Lewy bodies, Lewy neurites, glial cytoplasmic inclusions), where it colocalized with α-synuclein in PD and MSA cases. By contrast, weak FBXO7 immunoreactivity was occasionally detected in tau-positive inclusions in AD and PSP. These findings suggest a role for FBXO7 in the pathogenesis of the synucleinopathies.


Cardiovascular Research | 2008

A crucial role of caldesmon in vascular development in vivo

Ping-Pin Zheng; Lies-Anne Severijnen; Marcel van der Weiden; Rob Willemsen; Johan M. Kros

AIMS We explored the in vivo effects of knockdown of caldesmon on vascular development in zebrafish. METHODS AND RESULTS We investigated the effects of caldesmon knockdown on the vascular development in a zebrafish model with special attention for the trunk and head vessels including the aortic arches. We examined the developing fishes at various time points. The vascular abnormalities observed in the caldesmon morphants were morphologically and functionally characterized in detail in fixed and living embryos. The knockdown of caldesmon caused serious defects in vasculogenesis and angiogenesis in zebrafish morphants, and the vascular integrity and blood circulation were concomitantly impaired. CONCLUSION The data provide the first functional assessment of the role of caldesmon in vascular development in vivo, indicating that this molecule plays a crucial role in vasculogenesis and angiogenesis in vivo. Interfering with caldesmon opens new therapeutic avenues for anti-angiogenesis in cancer and ischaemic cardiovascular disease.


Cell Adhesion & Migration | 2007

Hela l-CaD is implicated in the migration of endothelial cells/endothelial progenitor cells in human neoplasms.

Ping-Pin Zheng; Marcel van der Weiden; Johan M. Kros

Caldesmon (CaD) is a major actin-binding protein distributed in a variety of cell types. No functional differences among the isoforms in in vitro studies were found so far. In a previous study we found that the low molecular caldesmon isoform (Hela l-CaD) is expressed in endothelial cells (ECs)/endothelial progenitor cells (EPCs) in tumor vasculature of various human tumors. Activation of cell motility is necessary for the navigation of the tip ECs during angiogenesis, and migration of EPCs from the bone marrow during vasculogenesis. In the present study we searched for features of motility and the intracellular expression sites of Hela l-CaD in ECs/EPCs of various human tumors under histologically preserved microenviroment. We discovered a variety of motility-related cell protrusions like filopodia, microspikes, lamellipodia, podosomes, membrane blebs and membrane ruffles in the activated ECs/EPCs. Hela l-CaD appeared to be invariably expressed in the subregions of these cell protrusions. The findings suggest that Hela l-CaD is implicated in the migration of ECs/EPC in human neoplasms where they contribute to tumor vasculogenesis and angiogenesis.


Genes, Chromosomes and Cancer | 1999

Identification of a homozygous deletion at 8p12–21 in a human prostate cancer xenograft

Dirk C. J. G. van Alewijk; Marcel van der Weiden; Bert J.F.M.M. Eussen; Lydia D. Van Den Andel-Thijssen; Conny C. E. M. van Eekelen; Jose J. Knig; Gert J. van Steenbrugge; Winand N. M. Dinjens; Jan Trapman

One of the most frequent genetic abnormalities in prostate cancer is loss of the complete or part of the short arm of chromosome 8, indicating the localization of one or more tumor suppressor genes on this chromosomal arm. Using allelotyping, a frequently deleted region in prostate cancer in a genetic interval of approximately 17 cM between sequence tagged sites D8S87 and D8S133 at chromosome arm 8p12–21 was previously detected. A detailed physical map of this region is now available. Using known and novel polymorphic and nonpolymorphic sequence tagged sites in this interval, a search for homozygous deletions in DNAs from 14 prostate cancer‐derived cell lines and xenografts was carried out. In DNA from xenograft PC133, the presence of a small homozygously deleted region of 730–1,320 kb was unambiguously established. At one site, the deletion disrupts the Werner syndrome gene. Data from allelotyping were confirmed and extended by fluorescence in situ hybridization analysis of PC133 chromosome spreads using centromere, YAC, and PAC chromosome 8 probes. Genes Chromosomes Cancer 24:119–126, 1999.


Cancer Biology & Therapy | 2007

Hela l-CaD undergoes a DNA replication-associated switch in localization from the cytoplasm to the nuclei of endothelial cells/endothelial progenitor cells in human tumor vasculature

Ping-Pin Zheng; Marcel van der Weiden; Peter A. E. Sillevis Smitt; Theo M. Luider; Johan M. Kros

Caldesmon (CaD) is a major actin-binding protein distributed in a variety of cell types. So far no diversity in functions of the different isoforms were found in in vitro studies. The low molecular weight isoform (Hela l-CaD) was detected in the vasculature of a variety of tumor types in our previous study. Proliferation of endothelial cells/endothelial progenitor cells is a crucial event for formation of new blood vessels. Here we report the intranuclear translocation of Hela l-CaD in cell cycle activated ECs/EPCs in the vasculature of human tumors. The nuclear translocation coincides with phosphorylation of the molecule and the activation of intranuclear protein kinase p34cdc2. These findings point to a function of this molecule relating to DNA synthesis which is triggered by cell-cycle signalling pathways. The data challenge and update the generally accepted concept that CaD is a pure cytoplasmic protein in vitro study. It suggests that nuclear translocation of Hela l-CaD serves as an additional regulatory step in the control of mitotic initiation and triggers further investigations in the role of this protein in the regulation of nuclear functions.


Brain Pathology | 2010

Expression Sites of Colligin 2 in Glioma Blood Vessels

Dana Mustafa; Marcel van der Weiden; Ping-Pin Zheng; Alex L. Nigg; Theo M. Luider; Johan M. Kros

In a previous study using state‐of‐the‐art proteomic techniques, we identified colligin 2 (HSP47) as a glioma blood vessel‐specific protein. In the present study we precisely localized the expression of colligin 2 in the blood vessels of diffusely infiltrating gliomas and relate the expression to the distinct cellular components of the vessels by using multiple immunolabeling and confocal microscopy. We grouped the glioma blood vessels into morphological categories ranging from normal looking capillaries to vessels with hypertrophic and sclerotic changes. The expression patterns of various markers of endothelial and pericytic differentiation were correlated with the position of the cells in the vessels and the expression of colligin 2. We found that colligin 2 is expressed in all categories of glioma blood vessels in cells with endothelial and pericytic lineage. Expression of colligin 2 was also found in cells scattered around blood vessels and in few glial fibrillary acidic protein‐positive cells within the blood vessels. There is overlap in the expression of colligin 2 and the collagens type I and IV for which colligin 2 is a chaperon. We conclude that colligin 2 is expressed in all cellular components of glioma blood vessels and may serve as a general marker for active angiogenesis.


Journal of Neuropathology and Experimental Neurology | 2007

Intratumoral distribution of 1p loss in oligodendroglial tumors.

Johan M. Kros; Marcel van der Weiden; Ping-Pin Zheng; Wim C. J. Hop; Martin J. van den Bent; Mathilde C.M. Kouwenhoven

The favorable response of oligodendrogliomas correlates well with characteristic chromosomal losses, of which loss of the short arm of chromosome 1 is most predictive. Oligodendrogliomas are histopathologically heterogeneous tumors and, in addition to the classic honeycomb histology, fields of nonclassic histology are often encountered. Information about the distribution of 1p loss in various regions of oligodendroglioma is, therefore, important to interpret findings in tumor biopsies. In this study we investigated the distribution of 1p loss in multiple fields in 24 biopsy specimens of oligodendroglioma consisting of classic and nonclassic histology by fluorescent in situ hybridization and loss of heterozygosity analysis. By fluorescent in situ hybridization analysis, loss of 1p was found in all fields examined in 37% of the tumor samples, and no loss was detected in 46%. In fields of classic oligodendroglial and polar spongioblastoma-like histology, significantly more loss for 1p was found (p < 0.001 and p < 0.01, respectively). Although fluorescent in situ hybridization analysis indicated heterogeneity for 1p loss in the other 17% of tumors, loss of heterozygosity analysis of these samples pointed to homogeneity of 1p status in all fields. The 1p status of the fields with classic histology significantly correlated with the status of the other fields in the same tumors (Spearmans rho 0.918, p < 0.001). These results point to genotypic homogeneity for 1p in oligodendroglial tumors.


Neuro-oncology | 2017

Activation of CECR1 in M2-like TAMs promotes paracrine stimulation-mediated glial tumor progression

Changbin Zhu; Dana Mustafa; Ping-Pin Zheng; Marcel van der Weiden; Andrea Sacchetti; Maarten M. Brandt; Ihsan Chrifi; Dennie Tempel; Pieter J. M. Leenen; Dirk J. Duncker; Caroline Cheng; Johan M. Kros

BACKGROUND The majority of glioma-associated microglia/macrophages have been identified as M2-type macrophages with immune suppressive and tumor supportive action. Recently, the extracellular adenosine deaminase protein Cat Eye Syndrome Critical Region Protein 1 (CECR1) was shown to regulate macrophage maturation. In this study, we investigate the role of CECR1 in the regulation of the glioma-associated macrophage response. METHODS Expression of CECR1 was assessed in human glioma samples. CECR1-mediated macrophage response was studied in vitro, using donor derived CD14+ monocytes and the THP-1 monocytic cell line. The response of the human glioma cell line U87 to conditioned medium of macrophages preconditioned with recombinant human CECR1 or CECR1 silencing was also assessed. RESULTS CECR1 was strongly expressed in high-grade gliomas (P < .001) and correlated positively with the M2 phenotype markers in tumor-associated microglia/macrophages (TAMs) (overall, P < .05). In vitro studies confirmed the presence of a significantly higher level of CECR1 expression in M2-like macrophages exposed to U87 conditioned medium (P < .001). CECR1 knockdown or stimulation of macrophages affected differentiation toward the M2-like phenotype. Stimulation of U87 cells with conditioned medium of CECR1 knockdown or stimulated macrophages affected tumor cell proliferation and migration, coinciding with altered intracellular signaling of mitogen-activated protein kinase (MAPK). In glioma tissue samples, CECR1 expression correlated with Ki67 and MAPK signaling protein. CONCLUSIONS CECR1 is a potent regulator of TAM polarization and is consistently highly expressed by M2-type TAMs, particularly in high-grade glioma. Paracrine effects induced by CECR1 in M2-like TAMs activate MAPK signaling and stimulate the proliferation and migration of glioma cells.Background The majority of glioma-associated microglia/macrophages have been identified as M2-type macrophages with immune suppressive and tumor supportive action. Recently, the extracellular adenosine deaminase protein Cat Eye Syndrome Critical Region Protein 1 (CECR1) was shown to regulate macrophage maturation. In this study, we investigate the role of CECR1 in the regulation of the glioma-associated macrophage response. Methods Expression of CECR1 was assessed in human glioma samples. CECR1-mediated macrophage response was studied in vitro, using donor derived CD14+ monocytes and the THP-1 monocytic cell line. The response of the human glioma cell line U87 to conditioned medium of macrophages preconditioned with recombinant human CECR1 or CECR1 silencing was also assessed. Results CECR1 was strongly expressed in high-grade gliomas (P < .001) and correlated positively with the M2 phenotype markers in tumor-associated microglia/macrophages (TAMs) (overall, P < .05). In vitro studies confirmed the presence of a significantly higher level of CECR1 expression in M2-like macrophages exposed to U87 conditioned medium (P < .001). CECR1 knockdown or stimulation of macrophages affected differentiation toward the M2-like phenotype. Stimulation of U87 cells with conditioned medium of CECR1 knockdown or stimulated macrophages affected tumor cell proliferation and migration, coinciding with altered intracellular signaling of mitogen-activated protein kinase (MAPK). In glioma tissue samples, CECR1 expression correlated with Ki67 and MAPK signaling protein. Conclusions CECR1 is a potent regulator of TAM polarization and is consistently highly expressed by M2-type TAMs, particularly in high-grade glioma. Paracrine effects induced by CECR1 in M2-like TAMs activate MAPK signaling and stimulate the proliferation and migration of glioma cells.

Collaboration


Dive into the Marcel van der Weiden's collaboration.

Top Co-Authors

Avatar

Johan M. Kros

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Ping-Pin Zheng

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Theo M. Luider

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Rob Willemsen

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Winand N. M. Dinjens

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Dana Mustafa

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Lies-Anne Severijnen

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Peter J. Koudstaal

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge